The Journal of emergency medicine · 2025
Delivery of L-Epinephrine by Metered-Dose Inhaler Compared to Racemic Epinephrine by Nebulizer for the Treatment of Croup.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Novi Brian, Kahne Kimberly, Psihos Cassidy, Polla Victoria, Cerise Jane, Krief William
Аннотация
BACKGROUND: Racemic epinephrine is standard of care for moderate to severe croup. Metered-dose inhaler (MDI) was the most adopted method to replace nebulization during the SARS-CoV-2 pandemic. No study has previously evaluated the effectiveness of l-epinephrine MDI for the treatment of croup in an emergency department as compared to nebulized racemic epinephrine.
OBJECTIVE: We aim to demonstrate that l-epinephrine by MDI is effective and safe in the treatment of croup compared to racemic epinephrine. Our primary outcome was the requirement of additional doses of epinephrine.
METHODS: We conducted a retrospective, single-center study of pediatric patients 1-10 years of age diagnosed with croup from March 2020 to July 2023. We included patients who received either l-epinephrine metered-dose inhaler (LEM) or racemic epinephrine by nebulization (REN) for the treatment of croup. Data for l-epinephrine was collected prospectively.
RESULTS: There were 325 patients analyzed of which patients in 38 encounters were treated with LEM. The median age for patients was 2.6 years (IQR: 1.6, 4.4) and 75% were male. Respiratory viral testing revealed 14% positive for SARS-CoV-2. Patients that received LEM showed an improvement in Westley Croup Score (WCS) of 2 (IQR: -3, -2) at 30 minutes post-administration. When comparing LEM to REN, there was no statistical difference in need for repeat dosing, change in heart rate, return to care within 48 hours, or admission to the hospital.
CONCLUSION: In this study of l-epinephrine administered by MDI we did not observe any statistically significant differences compared to nebulized racemic epinephrine in the treatment of croup.
OBJECTIVE: We aim to demonstrate that l-epinephrine by MDI is effective and safe in the treatment of croup compared to racemic epinephrine. Our primary outcome was the requirement of additional doses of epinephrine.
METHODS: We conducted a retrospective, single-center study of pediatric patients 1-10 years of age diagnosed with croup from March 2020 to July 2023. We included patients who received either l-epinephrine metered-dose inhaler (LEM) or racemic epinephrine by nebulization (REN) for the treatment of croup. Data for l-epinephrine was collected prospectively.
RESULTS: There were 325 patients analyzed of which patients in 38 encounters were treated with LEM. The median age for patients was 2.6 years (IQR: 1.6, 4.4) and 75% were male. Respiratory viral testing revealed 14% positive for SARS-CoV-2. Patients that received LEM showed an improvement in Westley Croup Score (WCS) of 2 (IQR: -3, -2) at 30 minutes post-administration. When comparing LEM to REN, there was no statistical difference in need for repeat dosing, change in heart rate, return to care within 48 hours, or admission to the hospital.
CONCLUSION: In this study of l-epinephrine administered by MDI we did not observe any statistically significant differences compared to nebulized racemic epinephrine in the treatment of croup.